Futura Medical PLC
28 February 2007
For immediate release 28 February 2007
Futura Medical Plc
Launches DermaSys(R) as brand name for
proprietary drug delivery technology
Futura Medical plc (Futura), the AIM-listed pharmaceutical group that develops
innovative products for the consumer healthcare market, announces the launch of
DermaSys(R) as the brand name for its versatile gel technology for the rapid
delivery of drugs through the skin.
The DermaSys(R) technology was originally developed by Futura for use in the
Company's topical treatment for erectile dysfunction, MED2002. Futura is
continuing its assessment program for DermaSys(R) against a wide range of
generic drugs suited to topical delivery where substantial improvements in speed
of absorption and permeability across the skin would result in attractive
commercial opportunities. For more information please visit the Futura website
by clicking on the following link: http://www.futuramedical.co.uk/content/
products/delivery_technology.asp
DermaSys(R) is a versatile and bespoke technology which can be adapted to suit
the specific active compound being used and the therapeutic indication. Such
targeted delivery offers an optimised profile in terms of dose, onset time and
duration of effect as well as an improved safety profile through lower systemic
uptake and the reduced risk of side effects.
James Barder, Futura Medical's Chief Executive, said: 'We are pleased to
announce the launch of DermaSys(R) as the brand name of our proprietary drug
delivery technology. DermaSys(R) is an important asset within Futura and we
intend to continue to exploit its potential.'
For further information:
Futura Medical plc
James Barder, Chief Executive Tel: +44 (0) 1483 685 670
mail to: james.barder@futuramedical.co.uk www.futuramedical.co.uk
Media enquiries:
Buchanan Communications
Mark Court / Rebecca Dietrich Tel: +44 (0) 020 7466 5000
Notes
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for
the consumer healthcare market with a strong expertise in sexual health. The
Company is developing a portfolio of products and its strategy is to license
their manufacture and distribution to major pharmaceutical and healthcare
groups. Futura's primary focus is on over-the-counter products with particular
appeal to men and women who are reluctant to discuss potentially embarrassing
sexual matters with their doctors.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of
the London Stock Exchange.
www.futuramedical.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange